Sunitinib malate

Inquiry
For Research Use Only.
Category
Impurities
Cat.No.
NP3249
CAS
341031-54-7
Product Name
Sunitinib malate
Structure
Structure
Size Price Stock Quantity
1 g $439 In stock

Product Details

Description
Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.
Synonyms
Sunitinib malate; SU011248 L-malate salt; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid
IUPAC Name
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid
Molecular Weight
532.56
Molecular Formula
C22H27FN4O2.C4H6O5
Canonical SMILES
CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O
InChI
InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1
InChIKey
LBWFXVZLPYTWQI-IPOVEDGCSA-N
Melting Point
187-191°C
Purity
>98%
Appearance
Yellow to Orange Solid
Application
Angiogenesis Inhibitors
Form
Powder
Packaging
1 g
Products
Inquiry
Online Inquiry
×
USA
  • International: 1-631-504-6093
  • US & Canada (Toll free): 1-844-BOC(262)-0123
  • 45-16 Ramsey Road, Shirley, NY 11967, USA
  • Email: info@bocsci.com
  • Fax: 1-631-614-7828
UK
  • 44-20-3980-8385
  • 85 Great Portland Street, London, W1W 7LT
  • Email: info@bocsci.com
Quick Links
Copyright © 2025 BOC Sciences. All Rights Reserved.
Top
0
Inquiry Basket

Failed to load!

Delete selectedGo to checkout

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x